Bioquark, a biotech company based in the United States, has been given the go-ahead to begin research on 20 brain-dead patients, in an attempt to stimulate and regrow neurons and, literally, bring the patients back from the dead.
![]()
The technique is new and untested so the study will likely be controversial.
By implanting stem cells in the patient’s brain, in addition to treating the spinal cord with infusions of chemicals and nerve stimulation techniques (both of which have been shown to bring people out of comas), they hope to reboot the brain and jump-start neural activity.
The result could be people coming back to life.
There isn’t much evidence that this will work, though there is one well-known neurological researcher and a member of the American Academy of Neurology, Dr. Calixto Machado who is involved with the study as a panel expert.
![]()
Bioquark’s CEO, Ira Pastor, said that “to undertake such a complex initiative, we are combining biologic regenerative medicine tools with other existing medical devices typically used for stimulation of the central nervous system, in patients with other severe disorders of consciousness. We hope to see results within the first two to three months.”
He added, “it is a long-term vision of ours that a full recovery in such patients is a possibility, although that is not the focus of this first study.
SOURCE
The technique is new and untested so the study will likely be controversial.
By implanting stem cells in the patient’s brain, in addition to treating the spinal cord with infusions of chemicals and nerve stimulation techniques (both of which have been shown to bring people out of comas), they hope to reboot the brain and jump-start neural activity.
There isn’t much evidence that this will work, though there is one well-known neurological researcher and a member of the American Academy of Neurology, Dr. Calixto Machado who is involved with the study as a panel expert.
Bioquark’s CEO, Ira Pastor, said that “to undertake such a complex initiative, we are combining biologic regenerative medicine tools with other existing medical devices typically used for stimulation of the central nervous system, in patients with other severe disorders of consciousness. We hope to see results within the first two to three months.”
He added, “it is a long-term vision of ours that a full recovery in such patients is a possibility, although that is not the focus of this first study.
“It is a bridge to that eventuality.”MINDS
SOURCE